The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom.
- Resource Type
- Article
- Source
- Vaccines; Jun2021, Vol. 9 Issue 6, p598, 1p
- Subject
INFLUENZA INFLUENZA vaccines VACCINATION COST effectiveness ECONOMIC impact COVID-19 - Language
- ISSN
- 2076393X